Clinical Trials

Innovent Biologics announced that it has received Investigational New Drug (IND) approval from the China Food and Drug Administration (CFDA) to initiate clinical trials in China with…
Read More...

Immunomedics announced a clinical collaboration with AstraZeneca and its global biologics research and development arm, MedImmune, to evaluate the safety and efficacy of the combination…
Read More...

About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that…
Read More...

Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. provided an overview of their TAK-935/OV935 broad clinical development program. The companies plan to initiate three…
Read More...

Sirona Biochem Corp. announced that partner, Jiangsu Wanbang Biopharmaceuticals, has confirmed the Investigational New Drug (IND) submission to China’s Food and Drug Administration…
Read More...

Eisai Co., Ltd and Biogen Inc announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's…
Read More...

PIVOTAL and APRO have announced a close collaboration in 3 different oncology clinical trials to test new treatment strategies given in an innovative way. The 3 trials have been…
Read More...

Purdue Pharma announced successful completion of a first-in-human Phase 1 dose escalation study of tinostamustine in patients with relapsed or refractory hematological malignancies for…
Read More...

Aquinox Pharmaceuticals announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain…
Read More...

Seattle Genetics announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy…
Read More...

Prana Biotechnology received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the…
Read More...

Asterias Biotherapeutics announced enrollment and dosing of the first subject in the first-in-human Phase 1 clinical trial of AST-VAC2 in the United Kingdom. This initial clinical…
Read More...

Alexion Pharmaceuticals and Complement Pharma announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents…
Read More...

BlackThorn Therapeutics announced enrollment of the first healthy volunteers in a Phase 1 study of BTRX-335140, a kappa opioid receptor (KOR) antagonist that targets brain circuits that…
Read More...

Sensei Biotherapeutics announced the publication of data from the company’s multi-center Phase 1 clinical trial to assess safety and immunogenicity of SNS-301 (formerly PAN-301) in…
Read More...

Merck announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell…
Read More...

Novartis announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant…
Read More...

Syndax Pharmaceuticals and Nektar Therapeutics announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in…
Read More...

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The Phase 1…
Read More...

INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat cancer, announced that it has initiated a Phase 1 clinical…
Read More...